Combining immunotherapy with oncogene-targeted therapy: A new road for melanoma treatment

Frontiers in Immunology

Volumn 6, Issue FEB, 2015, Pages

  Aris, Mariana ^a   Barrio, María Marcela ^a  

^a Centro de Investigaciones Oncológicas Fundación Cáncer   (Argentina)

Author keywords

Combination therapy; Immunotherapy; Melanoma; Oncogene targeted therapy

Indexed keywords

ALPHA INTERFERON; B RAF KINASE; BMS 936559; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DABRAFENIB; DACARBAZINE; DASATINIB; DENDRITIC CELL VACCINE; DURVALUMAB; IMATINIB; INTERLEUKIN 2; IPILIMUMAB; MPDL 3280A; NIVOLUMAB; PEMBROLIZUMAB; PEPTIDE VACCINE; SORAFENIB; TICILIMUMAB; TRAMETINIB; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VEMURAFENIB; [3 (5 CHLORO 1H PYRROLO [2, 3 B] PYRIDINE 3 CARBONYL) 2, 4 DIFLUOROPHENYL] PROPANESULFONAMIDE;

ADOPTIVE CELL THERAPY; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CELL THERAPY; CLINICAL TRIAL (TOPIC); CUTANEOUS MELANOMA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; GENE TARGETING; HUMAN; IMMUNOMODULATION; MALIGNANT TRANSFORMATION; MELANOCYTE; MELANOMA; META ANALYSIS (TOPIC); MUTATION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; REVIEW; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ESCAPE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

EID: 84926610782     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00046     Document Type: Review

References (87)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin (2014) 64:9-29. doi:10.3322/caac.21208
2. Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daud A, et al. Melanoma, version 2.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw (2013) 11:395-407.
3. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 364:2507-16. doi:10.1056/NEJMoa1103782
4. Hauschild A, Grob J-J, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet (2012) 380:358-65. doi:10.1016/S0140-6736(12)60868-X
5. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 363:711-23. doi:10.1056/NEJMoa1003466
6. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet (2014) 6736:1-9. doi:10.1016/S0140-6736(14)60958-2
7. Bis S, Tsao H. Melanoma genetics: the other side. Clin Dermatol (2013) 31:148-55. doi:10.1016/j.clindermatol.2012.08.003
8. Berger MF, Hodis E, Heffernan TP, Deribe YL, Lawrence MS, Protopopov A, et al. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature (2012) 485:502-6. doi:10.1038/nature11071
9. Siroy AE, Boland GM, Milton DR, Roszik J, Frankian S, Malke J, et al. Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. J Invest Dermatol (2015) 135(2):508-15. doi:10.1038/jid.2014.366
10. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature (2002) 417:949-54. doi:10.1038/nature00766
11. Greaves WO, Verma S, Patel KP, Davies MA, Barkoh BA, Galbincea JM, et al. Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma. J Mol Diagn (2013) 15:220-6. doi:10.1016/j.jmoldx.2012.10.002
12. Nikolaev SI, Rimoldi D, Iseli C, Valsesia A, Robyr D, Gehrig C, et al. Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat Genet (2012) 44:133-9. doi:10.1038/ng.1026
13. Ribas A, Flaherty KT. BRAF targeted therapy changes the treatment paradigm in melanoma. Nat Rev Clin Oncol (2011) 8:426-33. doi:10.1038/nrclinonc.2011.69
14. Klein O, Clements A, Menzies AM, O'Toole S, Kefford RF, Long GV. BRAF inhibitor activity in V600R metastatic melanoma. Eur J Cancer (2013) 49:1073-9. doi:10.1016/j.ejca.2012.11.004
15. Trudel S, Odolczyk N, Dremaux J, Toffin J, Regnier A, Sevestre H, et al. The clinical response to vemurafenib in a patient with a rare BRAFV600DK601del mutation-positive melanoma. BMC Cancer (2014) 14:727. doi:10.1186/1471-2407-14-727
16. Trunzer K, Pavlick AC, Schuchter L, Gonzalez R, McArthur GA, Hutson TE, et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol (2013) 31:1767-74. doi:10.1200/JCO.2012.44.7888
17. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med (2012) 367:107-14. doi:10.1056/NEJMoa1203421
18. Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, et al. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol (2013) 31:3182-90. doi:10.1200/JCO.2012.47.7836
19. Prickett TD, Agrawal NS, Wei X, Yates KE, Lin JC, Wunderlich J, et al. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet (2009) 41:1127-32. doi:10.1038/ng.438.Analysis
20. Guo J, Si L, Kong Y, Flaherty KT, Xu X, Zhu Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol (2011) 29:2904-9. doi:10.1200/JCO.2010.33.9275
21. Kluger HM, Dudek AZ, McCann C, Ritacco J, Southard N, Jilaveanu LB, et al. A phase 2 trial of dasatinib in advanced melanoma. Cancer (2011) 117:2202-8. doi:10.1002/cncr.25766
22. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 331:1565-70. doi:10.1126/science.1203486
23. Aris M, Barrio MM, Mordoh J. Lessons from cancer immunoediting in cutaneous melanoma. Clin Dev Immunol (2012) 2012:192719. doi:10.1155/2012/192719
24. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science (1996) 271:1734-6. doi:10.1126/science.271.5256.1734
25. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med (2002) 8:793-800. doi:10.1038/nm730
26. Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol (2013) 31:616-22. doi:10.1200/JCO.2012.44.6112
27. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 28:3167-75. doi:10.1200/JCO.2009.26.7609
28. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 369:122-33. doi:10.1056/NEJMoa1302369
29. Hwu W, Topalian SL, Hwu P, Chen S, Salay TM, Alaparthy S, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 366(26):2455-65. doi:10.1056/NEJMoa1200694
30. Aris M, Tapia IJ, Mordoh J, Barrio MM. Cutaneous melanoma: molecular biology, risk factors and treatment options. Melanoma: Molecular Biology, Risk Factors and Treatment Options. Nova Publisher Group. p. 39-66.
31. Rosenberg SA, Sherry RM, Morton KE, Scharfman WJ, Yang JC, Topalian SL, et al. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol (2005) 175:6169-76. doi:10.4049/jimmunol.175.9.6169
32. Vacchelli E, Martins I, Eggermont A, Fridman WH, Galon J, Sautès-fridman C, et al. Peptide vaccines in cancer therapy trial watch. Oncoimmunology (2012) 1(9):1557-76. doi:10.4161/onci.22428
33. Hailemichael Y, Overwijk WW. Peptide-based anticancer vaccines: the making and unmaking of a T-cell graveyard. Oncoimmunology (2013) 2:e24743. doi:10.4161/onci.24743
34. Aris M, Zubieta MR, Colombo M, Arriaga JM, Bianchini M, Alperovich M, et al. MART-1-and gp100-expressing and-non-expressing melanoma cells are equally proliferative in tumors and clonogenic in vitro. J Invest Dermatol (2012) 132:365-74. doi:10.1038/jid.2011.312
35. Neller MA, López JA, Schmidt CW. Antigens for cancer immunotherapy. Semin Immunol (2008) 20:286-95. doi:10.1016/j.smim.2008.09.006
36. Nemunaitis J. Vaccines in cancer: GVAX, a GM-CSF gene vaccine. Expert Rev Vaccines (2005) 4:259-74. doi:10.1586/14760584.4.3.259
37. Barrio MM, de Motta PT, Kaplan J, von Euw EM, Bravo AI, Chacón RD, et al. A phase I study of an allogeneic cell vaccine (VACCIMEL) with GM-CSF in melanoma patients. J Immunother (2006) 29:444-54. doi:10.1097/01.cji.0000208258.79005.5f
38. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature (2007) 449:419-26. doi:10.1038/nature06175
39. Beer TM, Bernstein GT, Corman JM, Glode LM, Hall SJ, Poll WL, et al. Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer. Clin Cancer Res (2011) 17:4558-67. doi:10.1158/1078-0432.CCR-10-3223
40. Oshita C, Takikawa M, Kume A, Miyata H, Ashizawa T, Iizuka A, et al. Dendritic cell-based vaccination in metastatic melanoma patients: phase II clinical trial. Oncol Rep (2012) 28:1131-8. doi:10.3892/or.2012.1956
41. Bercovici N, Haicheur N, Massicard S, Vernel-Pauillac F, Adotevi O, Landais D, et al. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients. J Immunother (2008) 31:101-12. doi:10.1097/CJI.0b013e318159f5ba
42. Palucka AK, Ueno H, Connolly J, Kerneis-Norvell F, Blanck J-P, Johnston DA, et al. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. J Immunother (2006) 29:545-57. doi:10.1097/01.cji.0000211309.90621.8b
43. Benteyn D, Van Nuffel AMT, Wilgenhof S, Corthals J, Heirman C, Neyns B, et al. Characterization of CD8+ T-cell responses in the peripheral blood and skin injection sites of melanoma patients treated with mRNA electroporated autologous dendritic cells (TriMixDC-MEL). Biomed Res Int (2013) 2013:976383. doi:10.1155/2013/976383
44. Goldszmid RS, Idoyaga J, Bravo AI, Steinman R, Mordoh J, Wainstok R. Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma. J Immunol (2003) 171:5940-7. doi:10.4049/jimmunol.171.11.5940
45. Von Euw EM, Barrio MM, Furman D, Bianchini M, Levy EM, Yee C, et al. Monocyte-derived dendritic cells loaded with a mixture of apoptotic/necrotic melanoma cells efficiently cross-present gp100 and MART-1 antigens to specific CD8(+) T lymphocytes. J Transl Med (2007) 5:19. doi:10.1186/1479-5876-5-19
46. Von Euw EM, Barrio MM, Furman D, Levy EM, Bianchini M, Peguillet I, et al. A phase I clinical study of vaccination of melanoma patients with dendritic cells loaded with allogeneic apoptotic/necrotic melanoma cells. Analysis of toxicity and immune response to the vaccine and of IL-10-1082 promoter genotype as predictor of diseas. J Transl Med (2008) 6:6. doi:10.1186/1479-5876-6-6
47. Anguille S, Smits EL, Lion E, van Tendeloo VF, Berneman ZN. Clinical use of dendritic cells for cancer therapy. Lancet Oncol (2014) 15:e257-67. doi:10.1016/S1470-2045(13)70585-0
48. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res (2011) 17:4550-7. doi:10.1158/1078-0432.CCR-11-0116
49. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol (2008) 26:5233-9. doi:10.1200/JCO.2008.16.5449
50. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol (2005) 23:2346-57. doi:10.1200/JCO.2005.00.240
51. Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Hershkovitz L, et al. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res (2010) 16:2646-55. doi:10.1158/1078-0432.CCR-10-0041
52. Tarhini AA, Kirkwood JM, Gooding WE, Cai C, Agarwala SS. Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy. J Clin Oncol (2007) 25:3802-7. doi:10.1200/JCO.2006.10.2822
53. Shaker MA, Younes HM. Interleukin-2: evaluation of routes of administration and current delivery systems in cancer therapy. J Pharm Sci (2009) 98:2268-98. doi:10.1002/jps.21596
54. Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res (2004) 10:1670-7. doi:10.1158/1078-0432.CCR-1103-3
55. Sangfelt O, Erickson S, Grander D. Mechanisms of interferon-induced cell cycle arrest. Front Biosci (2000) 5:D479-87. doi:10.2741/Sangfelt
56. Jewell AP, Worman CP, Lydyard PM, Yong KL, Giles FJ, Goldstone AH. Interferon-alpha up-regulates bcl-2 expression and protects B-CLL cells from apoptosis in vitro and in vivo. Br J Haematol (1994) 88:268-74. doi:10.1111/j.1365-2141.1994.tb05017.x
57. Sangfelt O, Strander H. Apoptosis and cell growth inhibition as antitumor effector functions of interferons. Med Oncol (2001) 18:3-14. doi:10.1385/MO:18:1:3
58. Bekisz J, Baron S, Balinsky C, Morrow A, Zoon KC. Antiproliferative properties of type I and type II interferon. Pharmaceuticals (Basel) (2010) 3:994-1015. doi:10.3390/ph3040994
59. Tang N, Wang L, Esko J, Giordano FJ, Huang Y, Gerber H-P, et al. Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell (2004) 6:485-95. doi:10.1016/j.ccr.2004.09.026
60. Raig ET, Jones NB, Varker KA, Benniger K, Go MR, Biber JL, et al. VEGF secretion is inhibited by interferon-alpha in several melanoma cell lines. J Interferon Cytokine Res (2008) 28:553-61. doi:10.1089/jir.2008.0118
61. Prasanna SJ, Saha B, Nandi D. Involvement of oxidative and nitrosative stress in modulation of gene expression and functional responses by IFNgamma. Int Immunol (2007) 19:867-79. doi:10.1093/intimm/dxm058
62. Konjevic G, Mirjacic Martinovic K, Vuletic A, Babovic N. In-vitro IL-2 or IFN-a-induced NKG2D and CD161 NK cell receptor expression indicates novel aspects of NK cell activation in metastatic melanoma patients. Melanoma Res (2010) 20:459-67. doi:10.1097/CMR.0b013e32833e3286
63. Konjevic G, Mirjacic-Martinovic K, Vuletic A, Babovic N. In vitro increased natural killer cell activity of metastatic melanoma patients with interferon-α alone as opposed to its combination with 13-cis retinoic acid is associated with modulation of NKG2D and CD161 activating receptor expression. J BUON (2012) 17:761-9. doi:10.1016/S0959-8049(12)71706-9
64. Draube A, Klein-González N, Mattheus S, Brillant C, Hellmich M, Engert A, et al. Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis. PLoS One (2011) 6:e18801. doi:10.1371/journal.pone.0018801
65. Leonhartsberger N, Ramoner R, Falkensammer C, Rahm A, Gander H, Höltl L, et al. Quality of life during dendritic cell vaccination against metastatic renal cell carcinoma. Cancer Immunol Immunother (2012) 61:1407-13. doi:10.1007/s00262-012-1207-7
66. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med (2004) 10:909-15. doi:10.1038/nm1100
67. Huber ML, Haynes L, Parker C, Iversen P. Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst (2012) 104:273-9. doi:10.1093/jnci/djr514
68. Madan RA, Gulley JL, Fojo T, Dahut WL. Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. Oncologist (2010) 15:969-75. doi:10.1634/theoncologist.2010-0129
69. Sumimoto H, Imabayashi F, Iwata T, Kawakami Y. The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med (2006) 203:1651-6. doi:10.1084/jem.20051848
70. Khalili JS, Liu S, Rodríguez-Cruz TG, Whittington M, Wardell S, Liu C, et al. Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clin Cancer Res (2012) 18:5329-40. doi:10.1158/1078-0432.CCR-12-1632
71. Knight DA, Ngiow SF, Li M, Parmenter T, Mok S, Cass A, et al. Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J Clin Invest (2013) 123:1371-81. doi:10.1172/JCI66236DS1
72. De Andrade LF, Ngiow SF, Stannard K, Rusakiewicz S, Kalimutho M, Khanna KK, et al. Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma. Cancer Res (2014) 74(24):7298-308. doi:10.1158/0008-5472.CAN-14-1339
73. Boni A, Cogdill AP, Dang P, Udayakumar D, Njauw C-NJ, Sloss CM, et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res (2010) 70:5213-9. doi:10.1158/0008-5472.CAN-10-0118
74. Comin-Anduix B, Chodon T, Sazegar H, Matsunaga D, Mock S, Jalil J, et al. The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations. Clin Cancer Res (2010) 16:6040-8. doi:10.1158/1078-0432.CCR-10-1911
75. Callahan MK, Masters G, Pratilas CA, Ariyan C, Katz J, Kitano S, et al. Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor. Cancer Immunol Res (2014) 2:70-9. doi:10.1158/2326-6066.CIR-13-0160
76. Wilmott JS, Scolyer RA, Long GV, Hersey P. Combined targeted therapy and immunotherapy in the treatment of advanced melanoma. Oncoimmunology (2012) 1:997-9. doi:10.4161/onci.19865
77. Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, Ferrone CR, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res (2013) 19:1225-31. doi:10.1158/1078-0432.CCR-12-1630
78. Ribas A, Hodi FS, Callahan MK, Konto C, Wolchok JD. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med (2013) 368:1365-6. doi:10.1056/NEJMc1301264
79. Hantschel O, Rix U, Superti-Furga G. Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leuk Lymphoma (2008) 49:615-9. doi:10.1080/10428190801896103
80. Kreutzman A, Ilander M, Porkka K, Vakkila J, Mustjoki S. Dasatinib promotes Th1-type responses in granzyme B expressing T-cells. Oncoimmunology (2014) 3:e28925. doi:10.4161/onci.28925
81. Schade AE, Schieven GL, Townsend R, Jankowska AM, Susulic V, Zhang R, et al. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood (2008) 111:1366-77. doi:10.1182/blood-2007-04-084814
82. Lowe DB, Bose A, Taylor JL, Tawbi H, Lin Y, Kirkwood JM, et al. Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma. Oncoimmunology (2014) 3:e27589. doi:10.4161/onci.27589
83. Yang Y, Liu C, Peng W, Lizée G, Overwijk WW, Liu Y, et al. Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40. Blood (2012) 120:4533-43. doi:10.1182/blood-2012-02-407163
84. Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest (2007) 117:1147-54. doi:10.1172/JCI31178
85. Sørensen RB, Berge-Hansen L, Junker N, Hansen CA, Hadrup SR, Schumacher TNM, et al. The immune system strikes back: cellular immune responses against indoleamine 2,3-dioxygenase. PLoS One (2009) 4:e6910. doi:10.1371/journal.pone.0006910
86. Kumar KGS, Liu J, Li Y, Yu D, Thomas-Tikhonenko A, Herlyn M, et al. Raf inhibitor stabilizes receptor for the type I interferon but inhibits its anti-proliferative effects in human malignant melanoma cells. Cancer Biol Ther (2007) 6:1437-41. doi:10.4161/cbt.6.9.4569
87. Liu C, Peng W, Xu C, Lou Y, Zhang M, Wargo JA, et al. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res (2013) 19:393-403. doi:10.1158/1078-0432.CCR-12-1626